ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Publication In Clinical Cancer Research Confirms Ability Of Peregrine's Bavituximab To Target Tumor Blood Vessels With Excellent Specificity
Peregrine
Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical
company developing monoclonal antibodies for the treatment of cancer and
hepatitis C virus infection, reported publication of a new
preclinical study in Clinical Cancer Research that supports the specific
tumor targeting properties of the company's novel anti-phosphatidylserine
(anti-PS) antibody platform. Peregrine's most advanced anti-PS monoclonal
antibody, bavituximab, is currently in Phase II cancer trials in
combination with chemotherapy.
The newly published study demonstrates that in a model of prostate
cancer, bavituximab's phosphatidylserine target is specifically exposed in
tumors, but not in normal tissues. When labeled with a radioisotope,
bavituximab preferentially targeted the tumor blood vessels, strongly
localizing to the tumors rather than normal organs. The study was conducted
by Dr. Philip Thorpe and his colleagues at UT Southwestern Medical Center
and is published in the March 1 issue of Clinical Cancer Research. It is
the latest in a series of preclinical studies that have confirmed important
elements of the mechanism of action of bavituximab.
"These results confirming the high specificity of bavituximab to target
tumor blood vessels with little or no localization to normal tissues
support the good safety profile and encouraging signs of anti-tumor
activity seen to date with bavituximab," said Dr. Thorpe, professor of
pharmacology at UT Southwestern and a member of Peregrine's Scientific
Resource Board. "Bavituximab's ability to achieve unusually clear images of
tumors in living animals also suggests that it might have utility for the
non-invasive imaging of tumors in cancer patients. Although the study was
conducted in rats bearing prostate tumors, we expect that the observations
will extend to other solid tumor types as well."
In the study, researchers administered radiolabeled bavituximab to rats
with prostate tumors and then conducted molecular imaging studies of the
rats over the next several days. The results showed that radiolabeled
bavituximab localized to the tumor blood vessels with great specificity. In
these subjects, 22 times as much bavituximab localized to the tumor
compared to the liver when measured 72 hours post-injection. The study
further showed no specific localization of bavituximab to blood or other
tissues including the heart, kidney, intestine, muscle, bone and brain. The
tumor blood vessel-selective targeting observed in vivo in the study was
confirmed by further bio-distribution analyses and by histology studies.
"This important new peer-reviewed study reinforces earlier evidence
that bavituximab targets tumor blood vessels with excellent specificity,"
said Steven W. King, president and CEO of Peregrine. "As we continue to
advance the cancer clinical program for bavituximab, these types of studies
are expanding the body of scientific evidence demonstrating the highly
specific nature of bavituximab's ability to target PS on tumor blood
vessels."
Bavituximab is a monoclonal antibody that binds to a phospholipid
called phosphatidylserine that is usually located inside normal cells, but
which becomes exposed on the outside of the cells that line the blood
vessels of tumors, creating a specific target for anti-cancer treatments.
Bavituximab is believed to help mobilize the body's immune system to
destroy the blood vessels needed for tumor growth and spread. In a Phase Ib
pilot trial in advanced cancer patients, bavituximab plus chemotherapy
appeared to have a safety profile consistent with chemotherapy alone and
showed positive signs of clinical activity, achieving objective response or
disease stabilization in 50% of the evaluable patients. Peregrine has
received regulatory approval to conduct three Phase II trials to study the
anti-tumor effects of bavituximab in combination with chemotherapy. These
include a breast cancer trial of bavituximab in combination with docetaxel
that is currently enrolling patients, a breast cancer protocol assessing
bavituximab in combination with carboplatin plus paclitaxel and a non-small
cell lung cancer protocol assessing bavituximab in combination with
carboplatin and paclitaxel. Bavituximab is in clinical trials in the U.S.
in patients with advanced solid tumors and in patients co-infected with HCV
and HIV.
The study, "Vascular Imaging of Solid Tumors in Rats with a Radioactive
Arsenic-Labeled Antibody that Binds Exposed Phosphatidylserine," by Marc
Jennewein, Matthew A. Lewis, Dawen Zhao, Edward Tsyganov, Nikolai Slavine,
Jin He, Linda Watkins, Vikram D. Kodibagkar, Sean O'Kelly, Padmakar
Kulkarni, Peter P. Antich, Alex Hermanne, Frank Rosch, Ralph P. Mason and
Philip E. Thorpe, appears in the March 1, 2008 issue of Clinical Cancer
Research.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a
portfolio of innovative product candidates in clinical trials for the
treatment of cancer and hepatitis C virus (HCV) infection. The company is
pursuing three separate clinical programs in cancer and HCV infection with
its lead product candidates bavituximab and Cotara(R). Peregrine also has
in-house manufacturing capabilities through its wholly owned subsidiary
Avid Bioservices, Inc. (http://www.avidbio.com), which provides development
and bio-manufacturing services for both Peregrine and outside customers.
Additional information about Peregrine can be found at
http://www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release which are not
purely historical, including statements regarding Peregrine
Pharmaceuticals' intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future are forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. The forward-looking statements involve risks and uncertainties
including, but not limited to, the risk that comparable targeting results
will not be achieved in other solid tumor types. It is important to note
that the company's actual results could differ materially from those in any
such forward-looking statements. Factors that could cause actual results to
differ materially include, but are not limited to, uncertainties associated
with completing preclinical and clinical trials for our technologies; the
early stage of product development; the significant costs to develop our
products as all of our products are currently in development, preclinical
studies or clinical trials; obtaining additional financing to support our
operations and the development of our products; obtaining regulatory
approval for our technologies; anticipated timing of regulatory filings and
the potential success in gaining regulatory approval and complying with
governmental regulations applicable to our business. Our business could be
affected by a number of other factors, including the risk factors listed
from time to time in the company's SEC reports including, but not limited
to, the annual report on Form 10-K for the year ended April 30, 2007 and
the quarterly report on Form 10-Q for the quarter ended October 31, 2007.
The company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. Peregrine
Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to
update or revise any forward-looking statements in this press release.
Peregrine Pharmaceuticals, Inc.
http://www.peregrineinc.com
Publicarea în clinice de cancer de cercetare confirmã capacitatea lui de cãlãtor Bavituximab la þintã tumoare vasele de sânge, cu excelente de specificitatea - Publication In Clinical Cancer Research Confirms Ability Of Peregrine's Bavituximab To Target Tumor Blood Vessels With Excellent Specificity - articole medicale engleza - startsanatate